Epithelial physical barrier defects in chronic rhinosinusitis.

Abstract:

INTRODUCTION:Chronic rhinosinusitis (CRS) is a common upper airway disease with a prevalence of greater than 10% of the general population. Although the pathogenesis of CRS remains poorly understood, there is growing evidence indicating that epithelial physical barrier defects play an important role in CRS pathogenesis. Areas covered: Epithelial physical barriers are maintained by various intercellular junctions, especially tight junctions (TJs). Recent studies suggest that the expression of TJ molecules and epithelial barrier function in human nasal epithelium are modulated by various internal and external factors. This review summarizes recent advances regarding the structure, function, and regulating mechanisms of the epithelial physical barrier in the context of CRS. Expert opinion: Available data indicate that epithelial physical barrier defects in CRS can result from inhaled allergens, microbial or virus infections, cytokines, hypoxia, or zinc deficiency, among other causes. Several genes/molecules, such as SPINK5, S100A7, S100A8/9, PCDH1, NDRG1, SPRR, and p63 are involved in modulating the physical barrier function in the context of CRS. The exact mechanisms and molecular pathways that lead to these barrier defects, however, require additional study. Additional work is necessary to further explore the epithelial physical barrier function in normal and pathologic sinonasal mucosa.

authors

Jiao J,Wang C,Zhang L

doi

10.1080/1744666X.2019.1601556

subject

Has Abstract

pub_date

2019-06-01 00:00:00

pages

679-688

issue

6

eissn

1744-666X

issn

1744-8409

journal_volume

15

pub_type

杂志文章,评审
  • Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap.

    abstract:INTRODUCTION:Patients with features of both asthma and chronic obstructive pulmonary disease (COPD) ('asthma-COPD overlap') experience greater symptom burden and higher risk of adverse health outcomes than those with asthma or COPD alone. However, virtually no pharmacotherapy studies have been performed in this overlap...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2017.1273109

    authors: Lau EMT,Roche NA,Reddel HK

    更新日期:2017-05-01 00:00:00

  • Recent insights into CD4+ T-cell specificity and function in type 1 diabetes.

    abstract::Type 1 diabetes (T1D) is caused by T-cell-mediated destruction of the insulin-producing beta-cells in the pancreas. Genetic and immunological evidence from humans and mouse models indicates that CD4(+) T cells play a crucial role in the development and prevention of T1D. The dichotomy between CD4(+) T regulatory and e...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.3.4.557

    authors: Mannering SI,Brodnicki TC

    更新日期:2007-07-01 00:00:00

  • HMGB1 in nasal inflammatory diseases: a reappraisal 30 years after its discovery.

    abstract:INTRODUCTION:High mobility group protein box 1 (HMGB1) is a protein belonging to the alarmin family. HMGB1 has a relevant role in starting the inflammatory cascade by means of receptors, such as RAGE and TLR. HMGB1 supports transcription of many genes in interactions with many transcription factors, including NF-kB. Th...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2020.1752668

    authors: Ciprandi G,Bellussi LM,Passali GC,Damiani V,Passali D

    更新日期:2020-05-01 00:00:00

  • Prediction of treatment outcome and relapse in inflammatory bowel disease.

    abstract:INTRODUCTION:Prediction of treatment outcome and clinical relapse in patients with inflammatory bowel disease (IBD), either ulcerative colitis (UC) or Crohn's disease (CD), is particularly important because therapeutics for IBD are not always effective and patients in remission could frequently relapse. Because undergo...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2019.1593140

    authors: Kato J,Yoshida T,Hiraoka S

    更新日期:2019-06-01 00:00:00

  • A case for antibiotic perturbation of the microbiota leading to allergy development.

    abstract::The use of antibiotics to treat pathogenic bacterial infections has been one of the greatest contributions to human health, yet antibiotic use also perturbs the communities of commensal and symbiotic bacteria that reside in the intestine of mammals. The microbiota are critical for normal immune development and for mai...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2013.851603

    authors: Reynolds LA,Finlay BB

    更新日期:2013-11-01 00:00:00

  • Epigenetic modifications: novel therapeutic strategies for systemic sclerosis?

    abstract::Epigenetic modifications of gene expression comprise modifications of DNA by DNA methylation and modifications of the histone proteins by acetylation, methylation, SUMOylation or phosphorylation. DNA methylation in the promoter region of genes represses gene transcription. Histone modifications influence the structure...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.11.37

    authors: Jüngel A,Distler JH,Gay S,Distler O

    更新日期:2011-07-01 00:00:00

  • Novel therapies for the antiphospholipid syndrome.

    abstract::Antiphospholipid antibodies (aPL Abs) are associated with thrombosis in patients with the antiphospholipid syndrome (APS). There is strong evidence that aPL Abs are pathogenic in vivo from studies in animal models. Furthermore, there are now convincing data indicating that activation of complement is involved in those...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.4.2.193

    authors: Pierangeli SS

    更新日期:2008-03-01 00:00:00

  • Tuberculosis in the course of sarcoidosis treatment: is genotyping necessary for personalized therapy?

    abstract::Pathological similarities between sarcoidosis (SA) and tuberculosis (TB) suggest that mycobacterial antigen(s), in genetically different predisposed hosts, may be a cause of SA. The authors' work and other published comparative analyses of HLA and non-HLA alleles in patients with SA or TB from different ethnic groups ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.13.8

    authors: Dubaniewicz A,Zimmermann A,Dudziak M,Typiak M,Skotarczak M

    更新日期:2013-04-01 00:00:00

  • Combining desloratadine and pseudoephedrine in the treatment of seasonal allergic rhinitis.

    abstract::Nonsedating antihistamines are a first-line therapy in the management of allergic rhinitis. They relieve the majority of the histamine-mediated symptoms of the condition, including rhinorrhea, sneezing, and pruritus. The nonsedating antihistamine desloratadine is effective in alleviating the symptoms of both seasonal ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.2.4.519

    authors: Schenkel EJ

    更新日期:2006-07-01 00:00:00

  • CD40 ligand deficiency: treatment strategies and novel therapeutic perspectives.

    abstract:INTRODUCTION:CD40 ligand (CD40L) deficiency or X-linked Hyper-IgM syndrome is a severe primary immunodeficiency caused by mutations in the CD40L gene. Despite currently available treatments, CD40L-deficient patients remain susceptible to life-threatening infections and have poor long term survival. Areas covered: Here,...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2019.1573674

    authors: França TT,Barreiros LA,Al-Ramadi BK,Ochs HD,Cabral-Marques O,Condino-Neto A

    更新日期:2019-05-01 00:00:00

  • Concurrent use of antioxidants in cancer therapy: an update.

    abstract::Some chemotherapeutic agents and all radiation therapy generates reactive oxygen species (ROS), which induce apoptosis in cancer cells. As ROS play a role in drug-induced apoptosis, one might suspect that antioxidants may inhibit ROS and prevent apoptosis of cancer cells. In order to find an answer to whether or not t...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.2.6.931

    authors: Akbas HS,Timur M,Ozben T

    更新日期:2006-11-01 00:00:00

  • The Role of the Immune System in Ovarian Cancer and Implications on Therapy.

    abstract::Ovarian cancer is the leading cause of death from gynecologic malignancy in the United States. While the treatment options have improved with conventional cytotoxic chemotherapy and advanced surgical techniques, disease recurrence is common and fatal in nearly all cases. Current evidence suggests that the immune syste...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2016.1147957

    authors: Menderes G,Schwab CL,Black J,Santin AD

    更新日期:2016-06-01 00:00:00

  • Targeting signaling pathways with small molecules to treat autoimmune disorders.

    abstract::Chronic activation of immune responses, mediated by inflammatory mediators and involving different effector cells of the innate and acquired immune system characterizes autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease, psoriasis and septic shock syndrome. MAPKs are crucial intracellular m...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.4.1.93

    authors: Kaminska B,Swiatek-Machado K

    更新日期:2008-01-01 00:00:00

  • Managing immune diseases in the smartphone era: how have apps impacted disease management and their future?

    abstract::Immunology, similar to other areas of clinical science, is a data-rich discipline that involves a great deal of interaction between healthcare professionals and their patients. The focus of this editorial is to review the challenges and opportunities for mobile healthcare applications within immunology. It is clear th...

    journal_title:Expert review of clinical immunology

    pub_type: 社论,评审

    doi:10.1586/1744666X.2015.1010518

    authors: Gallagher J,O'Donoghue J,Car J

    更新日期:2015-04-01 00:00:00

  • A comparison of immunotherapy delivery methods for allergen immunotherapy.

    abstract:BACKGROUND:Allergic diseases are among the most common diseases in humans. Besides allergen avoidance, allergen-specific immunotherapy is the only causative treatment option. During recent years, many innovations of this therapy have emerged. METHODS:Selective literature research in Medline and PubMed, under the inclu...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1586/eci.13.25

    authors: Klimek L,Pfaar O

    更新日期:2013-05-01 00:00:00

  • Adalimumab for the treatment of psoriatic arthritis.

    abstract::Psoriatic arthritis (PsA) is a chronic inflammatory joint disease occurring in 6-39% of patients with psoriasis. Standard therapy of PsA includes nonsteroidal anti-inflammatory drugs, intra-articular steroids and disease-modifying antirheumatic drugs. Failure of standard therapy is an indication for anti-TNF-alpha the...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.09.50

    authors: Poddubnyy DA,Rudwaleit M

    更新日期:2009-11-01 00:00:00

  • Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency.

    abstract:INTRODUCTION:Secondary immunodeficiency is becoming a greater medical concern as the usage of immunosuppressive and biological treatments has increased. Individuals with certain medical conditions, such as hematological malignancies, can also have secondary immunodeficiency. Immunoglobulin replacement therapy (IGRT), w...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2020.1788939

    authors: Patel V,Cowan J

    更新日期:2020-07-01 00:00:00

  • Potential and limitations of regulatory T-cell therapy in solid organ transplantation.

    abstract::Over the past few years, the therapeutic potential of Treg has been highlighted in the field of autoimmune diseases and after allogeneic transplantation. The first hurdle for the therapeutic use of Treg is their insufficient numbers in non-manipulated individuals, in particular when facing strong immune activation and...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.2014.943191

    authors: Govender L,Pascual M,Golshayan D

    更新日期:2014-09-01 00:00:00

  • Opposing roles of leukotrienes and prostaglandins in fibrotic lung disease.

    abstract::Lung fibrosis is a devastating disease that involves a variable degree of inflammation, alveolar epithelial injury, fibroblast hyperplasia and the deposition of extracellular matrix. Standard therapies that consist of corticosteroids and immunosuppressive agents offer little benefit and most patients experience a prog...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.2.1.87

    authors: Moore BB,Peters-Golden M

    更新日期:2006-01-01 00:00:00

  • Defining a new molecular basis of systemic lupus erythematosus through transcriptional profiling.

    abstract::Data generated using high-throughput DNA microarrays are changing the way we think about systemic lupus erythematosus (SLE). The identification of an interferon gene-expression signature in the majority of patients with SLE, especially those with severe SLE, has stimulated substantial interest in targeting the interfe...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.3.6.913

    authors: Gaffney PM,Moser KL,Baechler EC

    更新日期:2007-11-01 00:00:00

  • Noninvasive methods to assess the risk of kidney transplant rejection.

    abstract::In current clinical practice, immune reactivity of kidney transplant recipients is estimated by monitoring the levels of immunosuppressive drugs, and by functional and/or histological evaluation of the allograft. The availability of assays that could directly quantify the extent of the recipient's immune response towa...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.09.36

    authors: Cravedi P,Mannon RB

    更新日期:2009-09-01 00:00:00

  • Psoriatic arthritis: lessons from imaging studies and implications for therapy.

    abstract:INTRODUCTION:Modern imaging may aid in the diagnosis, prognosis and monitoring of therapeutic response in psoriatic arthritis (PsA). Detection of osteitis and technical advances like whole body magnetic resonance imaging (MRI) exemplify the value of this technology. Areas covered: Ultrasound (US) provides a clinic-base...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1215245

    authors: Mathew AJ,Coates LC,Danda D,Conaghan PG

    更新日期:2017-02-01 00:00:00

  • The evolution of allergen and non-specific immunotherapy: past achievements, current applications and future outlook.

    abstract::Recent epidemiological studies estimated that more than 30% of European suffer from allergic rhinitis or conjunctivitis, while up to 20% suffer from asthma and 15% from allergic skin conditions, while for many other regions the prevalence is increasing. Allergen immunotherapy represents the only available treatment th...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2015.977260

    authors: Pajno GB,Nadeau KC,Passalacqua G,Caminiti L,Hobson B,Jay DC,Arasi S,Chiera F,Salzano G

    更新日期:2015-01-01 00:00:00

  • New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management.

    abstract:INTRODUCTION:Biologic drugs have revolutionized the treatment of moderate to severe psoriasis in recent years because of their high efficacy and low risk of toxicity. However, even within the group of biologic therapies, there are differences related to the different mechanisms of action. Areas covered: We review the m...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2018.1454835

    authors: Carrascosa JM,Del-Alcazar E

    更新日期:2018-04-01 00:00:00

  • Thymic stromal lymphopoietin and the pathophysiology of atopic disease.

    abstract::Thymic stromal lymphopoietin (TSLP) is an IL-7-related cytokine expressed predominantly by barrier epithelial cells. TSLP is a potent activator of several cell types, including myeloid-derived dendritic cells, monocytes/macrophages and mast cells. Recent studies have revealed an important role for TSLP in the initiati...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.09.45

    authors: Miazgowicz MM,Headley MB,Larson RP,Ziegler SF

    更新日期:2009-09-01 00:00:00

  • Pediatric inflammatory bowel disease: specificity of very early onset.

    abstract:INTRODUCTION:The incidence of inflammatory bowel disease (IBD) has increased over the last 50 years. It is now recognized that several genetic defects can express an IBD-like phenotype at very early onset (<6 years). AREAS COVERED:The aim of this review was to update knowledge concerning the specificity of IBD at onse...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2016.1184571

    authors: Capriati T,Cardile S,Papadatou B,Romano C,Knafelz D,Bracci F,Diamanti A

    更新日期:2016-09-01 00:00:00

  • Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

    abstract::Patients with systemic lupus erythematosus have a significantly increased risk of cardiovascular events due to atherosclerosis. Traditional cardiac risk factors cannot fully explain this increased risk. Recent evidence strongly suggests that atherosclerotic plaque is largely driven by inflammation and an active immuno...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.10.98

    authors: McMahon M,Hahn BH,Skaggs BJ

    更新日期:2011-03-01 00:00:00

  • Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus.

    abstract:INTRODUCTION:Despite the emergence of newer immunomodulating agents for systemic lupus erythematosus (SLE), a substantial proportion of patients still do not respond optimally. While the mechanisms for the differential responses to drug therapy are unclear, variation in drug exposure with the same dosing protocol relat...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1212659

    authors: Mok CC

    更新日期:2017-01-01 00:00:00

  • Baricitinib for the treatment of rheumatoid arthritis.

    abstract:INTRODUCTION:Rheumatoid arthritis (RA) is characterized by systemic synovitis causing joint destruction. With the development of biological disease-modifying anti-rheumatic drugs (bDMARDs) and combination of conventional DMARDs, clinical remission is perceived as an appropriate and realistic goal in many patients. Howe...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1214576

    authors: Kubo S,Nakayamada S,Tanaka Y

    更新日期:2016-09-01 00:00:00

  • Clinical management of patients with primary immunodeficiencies during the COVID-19 pandemic.

    abstract::Introduction: Patients affected by Inborn Errors of Immunity (IEI) represent a potential group-at-risk in the current COVID-19 pandemic. Studies on large and small cohorts of IEI reported a huge variability clinical manifestations associated to SARS-Cov-2, ranging from asymptomatic, mild, moderate/severe to death. A g...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2021.1873767

    authors: Quinti I,Mezzaroma I,Milito C

    更新日期:2021-01-15 00:00:00